Neonatal hypoxic ischemic encephalopathy-related biomarkers in serum and cerebrospinal fluid

作者：Lv Hongyan; Wang Qiuli; Wu Sujing; Yang Lihong; Ren Pengshun; Yang Yihui; Gao Jinsheng; Li Lianxiang^*

来源：Clinica Chimica Acta, 2015, 450: 282-297.

DOI：10.1016/j.cca.2015.08.021

• Newborn
• Hypoxic ischemic encephalopathy
• Biomarker
• Serum
• Cerebrospinal fluid

Neonatal hypoxic ischemic encephalopathy (HIE) is a common disease caused by perinatal asphyxia, a major cause of neonatal death, neurological behavior, and long-term disability. Currently, the diagnosis and prognosis of neonatal HIE are based on nervous system clinical manifestations, imaging and electrophysiological examination. These take time and late diagnosis allows brain injury to occur in newborns, so that infants of many brain injury missed the best treatment time, left with varying degrees of neurological sequelae. The use of biomarkers to monitor brain injury and evaluate neuroprotective effects might allow the early intervention and treatment of neonatal HIE to reduce mortality rates. This study reviewed the mechanism of neonatal hypoxic ischemic encephalopathy in relation to numerous brain-related biomarkers including NSE, S-100 beta, GFAP, UCH-L1, Tau protein, miRNA, LDH, and CK-BB. In early diagnosis of neonatal HIE, S-100 beta and activin A seems to be better biomarkers. Biomarkers with the greatest potential to predict long-term neurologic handicap of neonates with HIE are GFAP and UCH-L1 and when combined with other markers or brain imaging can increase the detection rate of HIE. Tau protein is a unique biological component of nervous tissues, and might have value for neonatal HIE diagnosis. Combination of more than two biological markers should be a future research direction.

• 出版日期2015-10-23
• 单位河北工程大学